Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	195 women with moderate to severe breast pain	Adverse effects 53/104 (51%) with toremifene 30 mg daily for 3 menstrual cycles 39/91 (43%) with placebo for 3 menstrual cycles	P = 0.45		Not significant
RCT Crossover design	62 women with cyclical mastalgia during at least 3 previous menstrual cycles	Headache 3/56 (5%) with oral toremifene 20 mg 2/56 (4%) with placebo	Significance not assessed
RCT Crossover design	62 women with cyclical mastalgia during at least 3 previous menstrual cycles	Nausea 2/56 (4%) with oral toremifene 20 mg 1/56 (2%) with placebo	Significance not assessed